Pyrimidines (including Hydrogenated) (e.g., Cytosine, Etc.) Patents (Class 514/49)
-
Publication number: 20130345165Abstract: Embodiments disclosed in the present application relate to a composition that can include a hepatitis C viral nucleoside polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof, a hepatitis C viral protease inhibitor, or pharmaceutically acceptable salt or prodrug thereof, and a hepatitis C viral non-nucleoside polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof. Additional embodiments disclosed relate to methods for treating a disease condition such as a hepatitis C virus infection, liver fibrosis and/or impaired liver function with a hepatitis C viral nucleoside polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof, a hepatitis C viral protease inhibitor, or pharmaceutically acceptable salt or prodrug thereof, and a hepatitis C viral non-nucleoside polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof.Type: ApplicationFiled: June 11, 2013Publication date: December 26, 2013Applicant: Hoffman La-Roche Inc.Inventors: Patrick F. Smith, Tom W. Chu, Janet Hammond
-
Publication number: 20130344138Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administration of a compound of formula I, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising such compound admixed with at least one pharmaceutically acceptable excipient.Type: ApplicationFiled: August 28, 2013Publication date: December 26, 2013Applicant: GILEAD CALISTOGA LLCInventors: Kamal D. PURI, Jerry B. EVARTS, Brian LANNUTTI, Neill GIESE
-
Publication number: 20130345164Abstract: This invention concerns methods of identifying treatments for treating various disorders and related computer products and systems. Also disclosed are methods for treating cellular proliferative disorders and use of compounds identified for such treatment.Type: ApplicationFiled: April 21, 2011Publication date: December 26, 2013Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEYInventors: Alexei Vazquez, Darren Carpizo, Arnold Levine
-
Publication number: 20130338096Abstract: A compound of the general formula (III): wherein X is O, S, NH or CH2; Y is O, S or NH; Z is O, S or CH2; R1 is C1-8 alkyl, especially C1-6 alkyl, preferably n-alkyl, e.g., n-pentyl or n-hexyl; at least one of R2 and R3 is H—[R4—R5]n—R6—, in which: H—[R4—R5]n— comprises an oligopeptide, R4 being an amino acid and R5 being an amino acid selected from proline, alanine, hydroxyproline, dihydroxyproline, thiazolidinecarboxylic acid (thioproline), dehydroproline, pipecolic acid (L-homoproline), azetidinecarboxylic acid, aziridinecarboxylic acid, glycine, serine, valine, leucine, isoleucine and threonine, R6 is a neutral, non-polar amino acid moiety that is bonded to R5 by a peptide bond, and n is 1, 2, 3, 4 or 5; and the other of R3 and R2 is H—[R4—R5]n-R6— or H; or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: August 20, 2013Publication date: December 19, 2013Applicants: CONSEJO SUPERIOR DE INVESTIGACIONES CEINTIFICAS, KATHOLIEKE UNIVERSITEIT LEUVENInventors: Jan Balzarini, Maria Jose Camarasa, Sonsoles Velazquez
-
Publication number: 20130336965Abstract: The present invention provides a compound of formula (A): as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.Type: ApplicationFiled: May 20, 2013Publication date: December 19, 2013Applicant: Novartis AGInventors: Matthew Burger, Joseph E. Drumm, III, Gisele Nishiguchi, Alice Rico, Robert Lowell Simmons, Benjamin Taft, Huw Tanner
-
Publication number: 20130338094Abstract: The present disclosure relates to compounds of formula (I-A) using the compounds wherein Ring A and the variables X, Y, R3a, R3b, R3c, R3d, R4, R5, R5?, and m are defined herein, to pharmaceutical compositions comprising the compounds, and methods of using the compounds.Type: ApplicationFiled: May 23, 2013Publication date: December 19, 2013Applicant: MILLENNIUM PHARMACEUTICALS, INC.Inventors: Stephen CRITCHLEY, Thomas G. Gant, Steven P. Langston, Edward J. Olhava, Stephane Peluso
-
Patent number: 8609066Abstract: The present invention relates to methods for determining whether blood flow is restricted in a blood vessel of an individual suspected of compromised blood flow in the vessel, the method comprising the steps of delivering UTP, a derivative thereof, or a salt thereof to the vessel, assessing blood flow quantitatively in the vessel by obtaining a value that correlates to blood flow in said vessel, comparing the obtained value with a reference value, and determining whether the individual has compromised blood flow based on the results of the comparison. The invention also provides for methods of diagnosing atherosclerotic and ischemic heart diseases using UTP, a derivative thereof, or a salt thereof, as well as methods for inducing maximal hyperemia for diagnostic purposes.Type: GrantFiled: December 27, 2012Date of Patent: December 17, 2013Inventor: Jaya Brigitte Rosenmeier
-
Pharmacological modulation of telomere length in cancer cells for prevention and treatment of cancer
Patent number: 8609623Abstract: Acyclic nucleoside analogs such as acyclovir, ganciclovir, penciclovir and the corresponding pro-drugs, i.e., valacyclovir, valganciclovir and famciclovir, respectively have been identified as inhibitors or antagonists of both telomerase (encoded by TERT) and reverse transcriptase encoded by L-1 (LINE-1) RT, and as useful for treating or preventing cancers induced or mediated by the two enzymes. Method of treating or preventing such cancers in patients involves administration of a therapeutically effective amount of a composition having an inhibitor or antagonist of the reverse transcriptases in cells of the patients. The inhibitor or antagonist blocks lengthening of telomeres in telomerase positive and telomerase negative cells. Methods and kits for detecting pathologically proliferating cells expressing TERT and L1RT are also disclosed.Type: GrantFiled: May 18, 2006Date of Patent: December 17, 2013Assignee: ALT Solutions Inc.Inventor: Igor E. Bondarev -
Patent number: 8609628Abstract: Disclosed are polycyclic polyether compounds of formula I and pharmaceutical compositions comprising such compounds. wherein R, OR1, and R2 are as defined herein. Also disclosed are methods of regulating mucus clearance in a cell, and methods of treating decreased mucus clearance or mucociliary dysfunction.Type: GrantFiled: January 23, 2012Date of Patent: December 17, 2013Assignee: University of North Carolina at WilmingtonInventors: Daniel G. Baden, William M. Abraham, Andrea J. Bourdelais, Sophie Michelliza
-
Publication number: 20130330297Abstract: 2? and/or 3? prodrugs of 1?, 2?, 3? or 4?-branchednucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.Type: ApplicationFiled: August 2, 2013Publication date: December 12, 2013Applicants: Idenix Pharmaceuticals, Inc., L'Universite Montpellier II (UMII), Centre National De La Recherche Scientifique (CNRS), Universita degli Studi di CagliariInventors: Richard Storer, Gilles Gosselin, Jean-Pierre Sommadossi, Paolo LaColla
-
Patent number: 8603999Abstract: Amphiphilic prodrugs of general formula A-X are disclosed, wherein A is a biologically active agent or may be metabolised to a biologically active agent; and X is selected from the group consisting of R, or up to three R moieties attached to a linker, Y1, Y2 or Y3, wherein R is selected from a group consisting of alkyl, alkenyl, alkynyl, branched alkyl, branched alkenyl, branched alkynyl, substituted alkyl, substituted alkenyl and substituted alkynyl groups and their analogues; Y1 is a linker group which covalently attached to an R group at one site and is attached to A at a further independent site; Y2 is a linker group which is covalently attached to two R groups at two independent sites and is attached to A at a further independent site; and Y3 is a linker group which is covalently attached to three R groups at three independent sites and is attached to A at a further independent site.Type: GrantFiled: December 4, 2009Date of Patent: December 10, 2013Assignee: Commonwealth Scientific and Industrial Research OrganisationInventors: Calum John Drummond, Sharon Marie Sagnella, Minoo Jalili Moghaddam, Xiaojuan Gong
-
Patent number: 8604000Abstract: The present invention relates to the use of a taste masking agent selected from the group of cellulose; starch; xanthan gum; gellan gum; alginate; galactomannans such as fenugreek, guar gum, tara gum, locust bean gum, and cassia gum; gum karaya; gum tragacanth; carrageenan; and mixture thereof, for improving one or more of mouth feel, taste, aftertaste and smell of a liquid aqueous nutritional composition comprising a nucleotide and/or a nucleoside. It also relates to a nutritional composition comprising an unsavory nucleotide and/or a nucleoside component, having improved sensory characteristics such as improved mouth feel, taste, aftertaste and smell. In particular, it relates to a composition comprising said un-savory nucleotide and/or a nucleoside component, in particular comprising an uridine-containing nucleotide and/or a nucleoside in combination with an unsavory edible oil, such as a fish oil.Type: GrantFiled: December 22, 2008Date of Patent: December 10, 2013Assignee: N.V. NutriciaInventors: Esther Jacqueline de Kort, Martine Groenendijk, Patrick Joseph Gerardus Hendrikus Kamphuis
-
Patent number: 8603998Abstract: In its many embodiments, the present invention provides a novel class of pyrimidine analogs of formula (V) as targeted mechanism-based modulators of cell cycle checkpoints. Cancers and/or malignancies can be treated by administration of a cell cycle checkpoint modulator of the invention. Also discussed are suitable combinations of the cell cycle checkpoint modulator with a checkpoint kinase inhibitor to produce synergistic apoptosis in cancer cells. The invention includes methods of treating cancers by administering the combination of the cell cycle checkpoint modulator and the checkpoint kinase inhibitor, pharmaceutical compositions comprising the activator as well as the combination and pharmaceutical kits.Type: GrantFiled: November 5, 2008Date of Patent: December 10, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Timothy J. Guzi, David A. Parry, Marc A. Labroli, Michael D. Dwyer, Kamil Paruch
-
Publication number: 20130324493Abstract: Provided herein are compositions comprising ningnanmycin or a derivative thereof, as well as their use for controlling or combating a fungal infection in a plant or plant part (e.g., a turfgrass).Type: ApplicationFiled: May 31, 2013Publication date: December 5, 2013Applicant: North Carolina State UniversityInventors: Bangya Ma, Lane P. Tredway
-
Publication number: 20130324491Abstract: This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2?-deoxy-?-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2?-deoxy-?-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2?-deoxy-?-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2?-deoxy-?-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.Type: ApplicationFiled: March 22, 2013Publication date: December 5, 2013Applicants: Idenix Pharmaceuticals, Inc., L'Universite Montpellier II, Centre National de la Recherche ScientifiqueInventors: Gilles Gosselin, Jean-Louis Imbach, Martin L. Bryant
-
Publication number: 20130324494Abstract: Novel compounds and pharmaceutical compositions are provided. In one aspect of the invention the compounds may be utilized in medical practice, for example, in treatment of cancer and immune disorders.Type: ApplicationFiled: August 8, 2013Publication date: December 5, 2013Applicant: Aposense Ltd.Inventors: Ilan ZIV, Hagit Grimberg
-
Publication number: 20130315863Abstract: A method and composition for treating a host infected with flavivirus or pestivirus comprising administering an effective flavivirus or pestivirus treatment amount of a described 1?, 2? or 3?-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.Type: ApplicationFiled: July 31, 2013Publication date: November 28, 2013Applicants: Universita' degli Studi di Cagliari, Idenix Pharmaceuticals, Inc.Inventors: Jean-Pierre SOMMADOSSI, Paolo LaColla
-
Publication number: 20130315862Abstract: A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1?, 2? or 3?-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.Type: ApplicationFiled: July 29, 2013Publication date: November 28, 2013Applicants: Universita' degli Studi di Cagliari, Idenix Pharmaceuticals, Inc.Inventors: Jean-Pierre Sommadossi, Paolo LaColla
-
Publication number: 20130315864Abstract: The present invention provides nucleoside phosphoramidate compounds of Formula I, where R1, R2a, R2b, R3, R4, R5a, R5b, R6, R7, R8a, R8b, M and W are as defined herein. The invention further includes pharmaceutical compositions comprising a compound of Formula I, methods of use of these compounds for treating a viral infection, and methods of producing these compounds.Type: ApplicationFiled: May 17, 2013Publication date: November 28, 2013Applicant: ENANTA PHARMACEUTICALS, INC.Inventors: Yat Sun Or, Jun Ma, Guoqiang Wang
-
Publication number: 20130315867Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.Type: ApplicationFiled: May 21, 2013Publication date: November 28, 2013Inventors: Christophe Claude PARSY, Francois-Rene ALEXANDRE, Cyril B. DOUSSON, David DUKHAN, Gilles GOSSELIN, Houcine RAHALI, Dominique SURLERAUX
-
Publication number: 20130316969Abstract: The invention is related to phosphorus substituted compounds with antiviral activity, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: March 21, 2013Publication date: November 28, 2013Applicant: Gilead Sciences, Inc.Inventor: Gilead Sciences, Inc.
-
Publication number: 20130310336Abstract: A method and composition for treating a host infected with flavivirus or pestivirus comprising administering an effective flavivirus or pestivirus treatment amount of a described 1?, 2? or 3?-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.Type: ApplicationFiled: November 13, 2012Publication date: November 21, 2013Applicants: UNIVERSITA DEGLI STUDI DI CAGLIARI, IDENIX PHARMACEUTICALS, INC.Inventors: Jean-Pierre SOMMADOSSI, Paolo LACOLLA
-
Publication number: 20130309195Abstract: The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: March 14, 2013Publication date: November 21, 2013Inventors: John O. Link, Jeromy J. Cottell, Teresa Alejandra Trejo Martin
-
Publication number: 20130310334Abstract: Disclosed are compounds, pharmaceutical compositions containing the compounds, uses of the compounds and compositions as modulators of histone methyltransferases, and methods for treating diseases influenced by modulation of histone methyltransferase activity.Type: ApplicationFiled: December 5, 2011Publication date: November 21, 2013Applicant: EPIZYME, INC.Inventors: Richard Chesworth, Kevin Wayne Kuntz, Edward James Olhava, Michael A. Patane
-
Patent number: 8586561Abstract: Provision of a novel combined therapy with ECyd, which therapy exhibits remarkable antitumor effect and gives less adverse effects. The invention provides an antitumor agent containing, in combination, 1-(3-C-ethynyl-?-D-ribopentofuranosyl)cytosine or a salt thereof and carboplatin.Type: GrantFiled: March 26, 2009Date of Patent: November 19, 2013Assignees: Taiho Pharmaceutical Co., Ltd.Inventor: Hiromi Kazuno
-
Patent number: 8580764Abstract: The present invention provides methods of treating a cell proliferative disorder, such as lung cancer and breast cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or a pyrroloquinolinyl-pyrrolidine-2,5-dione compound, such as (?)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione, in combination with a therapeutically effective amount of a second anti-proliferative agent, such as gemcitabine.Type: GrantFiled: July 1, 2011Date of Patent: November 12, 2013Assignee: ArQule, Inc.Inventors: Giovanni Abbadessa, Dennis S. France, Chang-Rung Chen, Thomas C. K. Chan
-
Patent number: 8580765Abstract: Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.Type: GrantFiled: September 11, 2012Date of Patent: November 12, 2013Assignee: Gilead Pharmasset LLCInventors: Michael Joseph Sofia, Jinfa Du, Peiyuan Wang, Dhanapalan Nagarathnam
-
Patent number: 8580753Abstract: Induction of telomere shortening, G2 arrest and apoptosis in telomerase positive cancer cells using acyclic nucleoside analogs has been disclosed. In addition, methods for impairment or prevention of tumorigenic telomerase positive cells from having a chance to grow into a tumor and methods for promoting tumor regression (decrease in size of an established tumor) using acyclic nucleoside analogs has been disclosed.Type: GrantFiled: January 6, 2012Date of Patent: November 12, 2013Assignee: ALT Solutions Inc.Inventor: Igor E. Bondarev
-
Publication number: 20130295051Abstract: The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes. An illustrative compound of the invention is shown below.Type: ApplicationFiled: September 2, 2011Publication date: November 7, 2013Inventors: Kenneth W. Bair, Alexandre J. Buckmelter, Bingsong Han, Jian Lin, Dominic J. Reynolds, Chase C. Smith, Zhongguo Wang, Xiaozhang Zheng
-
Publication number: 20130296261Abstract: The present invention relates to a method of treating cancer in a mammal by administration of 4-quinazolinamines and at least one additional anti-neoplastic compound. In particular, the method relates to a methods of treating cancers by administration of N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine and salts and solvates thereof in combination with at least one additional anti-neoplastic compound.Type: ApplicationFiled: October 26, 2012Publication date: November 7, 2013Applicant: SmithKline Beecham (Cork) LimitedInventors: Richard Buller, Mark Berger, Clet Niyikiza
-
Publication number: 20130295198Abstract: Methods for selecting chemotherapeutic agents for treating a cancer are provided that include the steps of providing a cancer cell sample having a population of bulk cancer cells and a population of cancer stem-like cells, culturing a first portion of the cancer cell sample in a hydrodynamic focusing bioreactor under microgravity conditions and for a period of time to selectively enhance the population of cancer stem-like cells and selectively kill the population of bulk cancer cells, contacting the cancer stem-like cells with one or more chemotherapeutic agents, and then selecting the one or more chemotherapeutic agents for treating the cancer if there is an increase in an amount of cytotoxicity. Methods for treating a cancer are also provided in which the identified chemotherapeutic agents are administered to a subject. Further provided are methods for identifying a test compound useful for treating a cancer.Type: ApplicationFiled: March 19, 2013Publication date: November 7, 2013Applicant: Marshall University Research CorporationInventor: Marshall University Research Corporation
-
Patent number: 8575118Abstract: The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.Type: GrantFiled: July 19, 2012Date of Patent: November 5, 2013Assignee: Gilead Sciences, Inc.Inventors: Hongyan Guo, Darryl Kato, Thorsten A. Kirschberg, Hongtao Liu, John O. Link, Michael L. Mitchell, Jay P. Parrish, Jianyu Sun, James Taylor, Elizabeth M. Bacon, Eda Canales, Aesop Cho, Choung U. Kim, Jeromy J. Cottell, Manoj C. Desai, Randall L. Halcomb, Michael Graupe, Evan S. Krygowski, Scott E. Lazerwith, Qi Liu, Richard Mackman, Hyung-Jung Pyun, Joseph H. Saugier, James Trenkle, Winston C. Tse, Randall W. Vivian, Scott D. Schroeder, William J. Watkins, Lianhong Xu
-
Publication number: 20130288994Abstract: A large volume infusion dosage form of gemcitabine, comprising a stable large volume solution of gemcitabine or its pharmaceutically acceptable salt in an aqueous vehicle filled in a large volume infusion container, wherein the solution is ready-to-be-infused.Type: ApplicationFiled: April 26, 2013Publication date: October 31, 2013Applicant: SUN PHARMACEUTICAL INDUSTRIES LTD.Inventors: Samarth Kumar, Prashant Kane, Alok B. Namdeo, Subhas B. Bhowmick, Kirti Ganorkar
-
Publication number: 20130288995Abstract: The present invention provides administration methods for CDPC for treating stroke. CDPC was delivered via ECS at a concentration of 40 mmol/L-60 mmol/L. In a specific embodiment of the present invention, the concentration of CDPC administered is 50 mmol/L, CDPC is delivered at one time, the flow rate of administration is 0.2 ?L/min, the volume of CDPC is 1.33 ?L/mL of brain tissue, and the CDPC is administered in the caudate nucleus. The method can decrease the concentration of CDPC entering the brain and further decrease the dosage while improving efficacy. Thus, the result is improved and the probability of adverse effects due to the drug is reduced.Type: ApplicationFiled: June 21, 2013Publication date: October 31, 2013Inventor: Hongbin HAN
-
Publication number: 20130288996Abstract: Compounds represented by the formula 1: wherein each R individually is H, an aliphatic acyl group or an aromatic acyl group; A is selected from the group consisting of wherein X is selected from the group consisting of hydrogen, halo, alkoxy, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, amino, monoalkylamino, dialkylamino, cyano and nitro; are used to treat or prevent arthritis including rheumatoid arthritis.Type: ApplicationFiled: July 3, 2013Publication date: October 31, 2013Inventors: John A. Secrist, III, William R. Waud, Zhican Qu, Xiangmin Cui
-
Patent number: 8563042Abstract: The invention concerns a pharmaceutical composition containing micronized fenofibrate, a surfactant and a binding cellulose derivative, as solubilizing adjuvant, preferably hydroxypropylmethylcellulose. The cellulose derivative represents less than 20 wt. % of the composition. The association of micronized fenofibrate with a binding cellulose derivative, as solubilizing adjuvant and a surfactant enables enhanced bioavailability of the active principle. The invention also concerns a method for preparing said composition without using any organic solvent.Type: GrantFiled: June 25, 2010Date of Patent: October 22, 2013Assignee: EthypharmInventors: Bruno Criere, Pascal Suplie, Philippe Chenevier
-
Publication number: 20130273177Abstract: Provided herein is a pharmaceutical composition comprising an isoflavonoid derivative and a cyclodextrin. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions. In specific instances, provided herein are intravenous compositions and therapies.Type: ApplicationFiled: November 1, 2011Publication date: October 17, 2013Applicant: MARSHALL EDWARDS, INC.Inventor: Ofir Moreno
-
Patent number: 8557791Abstract: Provision of a novel combined therapy with ECyd, which therapy exhibits remarkable antitumor effect and gives less adverse effects. The invention provides an antitumor agent containing, in combination, 1-(3-C-ethynyl-?-D-ribopentofuranosyl) cytosine or a salt thereof and carboplatin.Type: GrantFiled: March 26, 2009Date of Patent: October 15, 2013Assignees: Taiho Pharmaceutical Co., Ltd.Inventor: Hiromi Kazuno
-
Publication number: 20130266591Abstract: The present invention relates to the use of a tri-substituted glycerol compound for the manufacture of a medicament for the treatment of hematological malignancies. The invention also refers to a kit-of-parts comprising such a medicament. Finally, the invention also relates to a corresponding method for the treatment of such conditions as well as to an in vitro method for determining the susceptibility of such malignant cells to a medicament as defined in the invention.Type: ApplicationFiled: June 5, 2013Publication date: October 10, 2013Inventors: Axel Rolf Zander, Francis Ayuk Ayuketang, Wolfgang Richter, Lutz Weber
-
Publication number: 20130266666Abstract: The present invention relates to the combination of PM01183 with several anticancer drugs, in particular other anticancer drugs selected from antitumor platinum coordination complexes, antimetabolites, mitotic inhibitors, anticancer antibiotics, topoisomerase I and/or II inhibitors, proteasome inhibitors, histone deacetylase inhibitors, nitrogen mustard alkylating agents, nitrosourea alkylating agents, nonclassical alkylating agents, estrogen antagonists, androgen antagonists, mTOR inhibitors, tyrosine kinase inhibitors, and other agents selected from aplidine, ET-743, PM02734 and PM00104, and the use of these combinations in the treatment of cancer.Type: ApplicationFiled: November 11, 2011Publication date: October 10, 2013Applicant: PHARMA MAR, S.A.Inventors: Victoria Moneo Ocaña, Gema Santamaría Núñez, Luis Francisco García Fernández, Carlos Maria Galmarini, María José Guillén Navarro, Pablo Manuel Avilés Marín
-
Patent number: 8551963Abstract: Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.Type: GrantFiled: November 5, 2009Date of Patent: October 8, 2013Assignee: Ambit Biosciences CorporationInventors: Julius L. Apuy, Darren E. Insko, Joyce J. James
-
Patent number: 8551965Abstract: A compound of formula (I) wherein Ar can be one six-membered or two fused six-membered aromatic rings; R8 and R9 can be hydrogen, alkyl, cycloalkyl, halogens, amino, alkylamino, dialkylamino, nitro, cyano, alkyoxy, aryloxy, thiol, alkylthiol, arythiol, or aryl; Q can be O, S or CY2, where Y may be H, alkyl or halogens; X can be O, NH, S, N-alkyl, (CHR2)m where m is 1 to 10, and CY2; Z can be O, S, NH, or N-alkyl; U? is H and U? can be H or CH2; wherein: T can be OH, H, halogens, O-alkyl, O-acyl, O-aryl, CN, NH2. or N3; T? and T? can be H or halogen; and W can be H or a phosphate group. Compounds show anti-viral activity, for example with respect to varicella zoster virus.Type: GrantFiled: September 24, 2010Date of Patent: October 8, 2013Assignees: University College Cardiff Consultants Limited, Rega FoundationInventors: Christopher McGuigan, Jan Balzarini
-
Publication number: 20130261045Abstract: The subject invention concerns materials and methods for treating or preventing a neurodegenerative condition or disease associated with ?-amyloid peptide deposition in neural tissue in a person or animal by administering a therapeutically effective amount of a polyphenol, or an analog, isomer, metabolite, or prodrug thereof, that increases expression or activity of a protein that exhibits ?-secretase activity. The subject invention also provides methods to increase ?-secretase expression and/or activity in cells by administering polyphenol flavonoids like (?)-epigallocatechin-3-gallate (EGCG) and epicatechin (EC), two polyphenols derived from green tea and other plants and that can be produced synthetically. Furthermore, there are provided methods to decrease or inhibit the production of A?1-40 or A?1-42 by administering the EGCG and EC compounds, their analogs, metabolites, and prodrugs.Type: ApplicationFiled: December 7, 2012Publication date: October 3, 2013Inventors: ROLAND DOUGLAS SHYTLE, JUN TAN
-
Publication number: 20130261074Abstract: Described are methods and compositions for treating cancer that include a dopamine receptor (DR) antagonist such as thioridazine and a chemotherapeutic agent. Optionally, the chemotherapeutic agent is a DNA synthesis inhibitor such as cytarabine or a microtubule inhibitor such as paclitaxel or docetaxel. The methods and compositions are useful for the treatment of cancers such as acute myeloid leukemia.Type: ApplicationFiled: March 15, 2013Publication date: October 3, 2013Inventors: Mickie Bhatia, Eleftherios Sachlos
-
Publication number: 20130261075Abstract: The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering 4-amino-1-(2-deoxy-2,2-difluoro-?-D-erythro-pentofuranosyl)pyrimidin-2(1H)-on 2?,2?-difluoro-2?-deoxycytidine, or a pharmaceutically acceptable salt thereof, and N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethy;-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, to a human in need thereof.Type: ApplicationFiled: December 20, 2011Publication date: October 3, 2013Inventors: Douglas J. DeMarini, Ngocdiep T. Le
-
Patent number: 8545897Abstract: Compounds of Formula I are useful for inhibition of CHK1 and/or CHK2. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.Type: GrantFiled: March 20, 2012Date of Patent: October 1, 2013Assignee: Array BioPharma Inc.Inventors: Yvan Le Huerou, James F. Blake, Indrani W. Gunwardana, Pete Mohr, Eli M. Wallace, Bin Wang, Mark Joseph Chicarelli, Michael Lyon
-
Publication number: 20130252918Abstract: Phosphorodiamidate derivatives of e.g. gemcitabine are provided for use in treating cancer. In one embodiment, the two amidate motifs each comprises NR?R? where R? is H and R? is CR5R6CO2R7, where R6 is H, R5 is the side chain, including H and C1, of a naturally occurring alpha amino acid, and R7 is branched or unbranched, substituted or unsubstituted, acyclic or cyclic alkyl, including t-butyl-CH2-, benzyl and C3 to C6 cycloalkyl. Formula (I).Type: ApplicationFiled: October 5, 2011Publication date: September 26, 2013Inventor: Christopher McGuigan
-
Publication number: 20130251766Abstract: The present invention generally relates to polymers and macromolecules, in particular, to polymers useful in particles such as nanoparticles. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. In some cases, the nanoparticle may contain a drug. Other aspects of the invention are directed to methods using nanoparticle libraries.Type: ApplicationFiled: May 10, 2013Publication date: September 26, 2013Applicant: Bind Therapeutics, Inc.Inventors: Stephen E. Zale, Mir Mukkaram Ali
-
Publication number: 20130251757Abstract: The present disclosure generally relates to methods of making nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol.Type: ApplicationFiled: December 13, 2012Publication date: September 26, 2013Inventors: Gregory Troiano, Michael Figa, Abhimanyu Sabnis
-
Publication number: 20130245549Abstract: Bioactive agents are embedded in a cross-linked dextran and coated with a bioresorbable polymer. When implanted in a mammal, the coated cross-linked dextran composition produces controlled release of the embedded bioactive agent.Type: ApplicationFiled: September 12, 2012Publication date: September 19, 2013Applicant: ROYER BIOMEDICAL, INC.Inventors: Garfield P. ROYER, Tatiana Bizikova